Invasive species cost trillions in damages: study
From river-clogging plants to disease-carrying insects, the direct economic cost of invasive species worldwide has averaged about $35 billion a year for decades, researchers said Monday.
Since 1960, damage from non-native plants and animals expanding into new territory has cost society more than $2.2 trillion, 17 times higher than previous estimates, they reported in the journal Nature Ecology & Evolution.
The accelerating spread of invasive species -- from mosquitoes to wild boar to tough-to-eradicate plants -- blights agriculture, spreads disease and drives the growing pace of species extinction.
Earlier calculations based on highly incomplete data were already known to fall far short of reality.
To piece together a more accurate picture, an international team of researchers led by Ismael Soto, a scientist at the University of South Bohemia in the Czech Republic, compiled data on 162 invasive species whose costs have been well documented in at least a handful of countries.
They then modelled the economic impact for 78 other countries such as Bangladesh and Costa Rica, for which no data was previously available.
"We expected an underestimation of invasion costs, but the magnitude was striking," Soto told AFP.
Due mainly to high volumes of trade and travel, tens of thousands of animal and plant species have taken root, sometimes literally, far from their places of origin.
Europe is by far the continent most affected by the phenomenon, followed by North America and Asia.
"Plants were the most economically damaging group, both for damage and management," Soto said. "Cost hotspots include urban coastal areas, notably in Europe, eastern China, and the US."
Animals can cause devastating damage too.
Wild boar, for example, destroy crops, cornfields and vineyards, while mosquitoes -- with expanding ranges due to global warming -- impose direct costs to human health by spreading diseases such as dengue and malaria.
Another example is Japanese knotweed, an invasive plant that is very common in Europe and requires costly eradication programmes.
"Our study is based on only 162 species," Soto noted. "Our figure is probably still an underestimate of a wider problem, and therefore the real economic costs could be even higher."
Using a broader definition -- including indirect costs such as lost income -- the UN's biodiversity expert group, IPBES, has calculated the total cost to society of invasive species at about $400 billion annually.
jmi/mh/klm/jhb
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
5 hours ago
- Epoch Times
Japanese Gardens Calm the Mind—Here's What Makes Them So Effective
The earliest major treatise on Japanese gardens dates back to the 11th century. Yet some of the ancient design principles—such as capturing the spirit of nature—are still in use today. Could there be something about this garden style that is especially good for fostering relaxation? Research shows that exposure to nature induces positive feelings, but not all green spaces are equally therapeutic, according to a Eye Movement and Lower Stress The study, published in Frontiers in Neuroscience, adds to our understanding of how garden viewing offers a prescription-free method of reducing physiological and psychological signs of stress.
Yahoo
5 hours ago
- Yahoo
What does lightning look like from space? See stunning photos from astronauts on ISS
It's safe to say that most of us have seen lightning here on Earth plenty of times – some of us have even been struck by it. But the natural phenomenon is one all but a few select individuals will ever have the chance to see from the vantage of 250 miles in orbit. Fortunately, a few astronauts over the years have been more than willing to generously share a glimpse of crashing lightning as seen from outer space. And you better believe it looks nothing like what we're used to seeing from the ground. The latest images of sky-splitting lightning came courtesy of two NASA astronauts who reached the International Space Station together in March after launching from NASA's Kennedy Space Center near Cape Canaveral, Florida. In May, Nichole Ayers and Anne McClain posted photos on social media site X of lightning roiling far, far beneath them. "This is what lightning looks like from the top down," McClain said in a post shared May 21. Here's a closer look at just what they managed to capture from above Earth's atmosphere. The images McClain and Ayers shared show electrostatic discharges – in other words, lightning – from above the clouds as they orbited in the International Space Station. In Ayers' post on X, she said she first observed lightning May 1 while suited up for a spacewalk outside the orbital outpost. She then managed to capture a few photos the next day, which she shared May 5. "I am so amazed by the view we have up here of our Earth's weather systems," Ayers posted. While it was unclear what part of Earth the lightning was striking in Ayers' photos, McClain said her images were captured over Alabama and Georgia. "Fast and furious, but also an incredible sight!" McClain said. The photos not only reveal the chaotic beauty of lightning, but could provide valuable orbital data to scientists studying the phenomenon back on Earth. Here's a look at some of the astronauts' photos: The photos were captured at speeds of 120 frames per second, with the depicted flashes only taking up one frame. The technique was pioneered by veteran NASA astronaut Don Pettit, who is renowned for his astral photography. Pettit, who had arrived in September 2024 for his third and most recent space station stint, departed April 19, 2025, with two cosmonauts before safely landing in Kazakhstan on his 70th birthday. Ayers and McClain, who also recently made headlines for completing a rare all-female spacewalk, are among seven people living at the International Space Station. The crew of Expedition 73 includes three Americans, three Russian cosmonauts and one Japanese spacefarer from the Japan Aerospace Exploration Agency (Jaxa.) McClain and Ayers are both part of a SpaceX mission known as Crew-10 that reached the space station in March 2025. Their arrival with JAXA astronaut Takuya Onishi and Roscosmos cosmonaut Kirill Peskov paved the way for the NASA astronauts who crewed the doomed Boeing Starliner to depart with the Crew-9 mission. Also at the station is NASA astronaut Jonny Kim, who reached the outpost in April 2025 with cosmonauts Sergey Ryzhikov and Alexey Zubritsky. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on Florida Today: Lightning from space: Astronauts post stunning weather images on X
CNBC
6 hours ago
- CNBC
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
I'm back in New York City after spending the last weekend in Chicago for the American Society of Clinical Oncology annual meeting. More than 5,000 research abstracts were presented or published at ASCO by pharmaceutical giants, biotech companies, researchers and oncologists. They included studies on existing drugs, experimental treatments, AI tools and ideas for improving patient care. Here are some data highlights and executive commentary from the larger companies I follow: AstraZeneca wins big (again) – The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the growth of a common type of breast cancer by more than a year in a large late-stage trial when used as an initial treatment. The results could expand the use of the drug and change the way the disease is treated for the first time in a decade. The study evaluated Enhertu in combination with a standard medicine called pertuzumab as a frontline treatment, meaning it was used in patients newly diagnosed with what's known as HER2-positive metastatic breast cancer. Patients who got the Enhertu combination lived for almost 41 months before their disease spread, while a group who received a standard three-drug treatment lived for about 27 months before the cancer advanced. David Fredrickson, executive vice president of AstraZeneca's oncology business, told CNBC that one in three patients who start treatment for this type of cancer are not able to receive a second type of therapy because their health worsened or they died. But the results show that the Enhertu combination could give "another third of patients a chance to potentially have a longer progression-free survival time and to benefit from a more effective frontline therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined with two other cancer treatments, doubled survival time for patients with an aggressive form of colorectal cancer compared to a standard treatment in a late-stage trial. It's good news for Pfizer, which has submitted the data to the Food and Drug Administration to expand Braftovi's approval label. The three-treatment combination included a standard chemotherapy, an antibody drug called cetuximab and Braftovi, which targets a cancer mutation called BRAF V600E. That combination also cut deaths by 51% and slashed the risk that the cancer would progress by 47% compared to a standard treatment during the trial. Pfizer's Chief Scientific Officer Chris Boshoff told CNBC that 10% to 15% of colorectal cancer patients have that specific mutation, and noted their survival rates are "particularly poor." "We're very proud of [the data] because for the first time, it really shows a true impact on survival for a disease that's very challenging to treat," he said. Gilead and Merck combo's breast cancer win — The popular drug Trodelvy from Gilead in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment in a late-stage trial. Gilead could benefit from higher sales of Trodelvy as it competes with Enhertu. The study examined patients with advanced triple-negative breast cancer whose tumors express PD-L1, the protein targeted by drugs like Keytruda. Around 15% of breast cancer cases are triple negative, making them more aggressive and difficult to treat, according to Gilead. The findings suggest that the combination of Trodelvy and Keytruda "will likely become a new front-line standard of care in this setting," Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement. A Merck, Daiichi Sankyo drug disappoints in lung cancer – Merck and Daiichi Sankyo on Thursday said they have withdrawn their U.S. application for an experimental treatment after it failed to prolong the lives of lung cancer patients in a late-stage trial. The drug, patritumab deruxtecan, is one of three so-called antibody drug conjugates that Merck has been working on with Daiichi Sankyo as it races to offset Keytruda's upcoming loss of exclusivity. The medication failed the trial's secondary goal of extending overall survival, which is defined as the length of time patients lived from the start of treatment. Those results, along with subsequent discussions with the FDA, led the companies to withdraw the application. But last year, the drug met the study's main goal of helping delay tumor progression compared to chemotherapy in patients who have been previously treated for non-small cell lung cancer with a mutation in a gene called EGFR. Marjorie Greene, Merck's head of oncology global clinical development, told CNBC that the "totality of the data couldn't support" the drug's application for approval. She called it a disappointment but noted that the company is learning from "what worked and what didn't work" and is still "fully investing" in refining the drug. Merck and Daiichi Sankyo plan on advancing the treatment into a late-stage development for breast cancer. Amgen's positive lung cancer data: The company's drug, Imdelltra, reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemotherapy, according to data from a late-stage trial. Imdelltra also extended median overall survival by more than five months compared to the standard-of-care chemotherapy. Amgen said the trial results are intended to support last year's accelerated approval of Imdelltra by the FDA. BONUS: Bristol Myers Squibb inks deal with BioNTech – Bristol Myers Squibb on Monday said it has agreed to pay up to $11.1 billion to partner with BioNTech and develop its next-generation cancer immunotherapy. The drug could take on Keytruda and new treatments in development by Summit Therapeutics and Pfizer. BioNTech is running late-stage studies on the drug in lung cancer and plans to start a phase three trial in triple-negative breast cancer this year. Feel free to send any tips, suggestions, story ideas and data to Annika at The FDA this week approved the first-ever AI platform for breast cancer prediction from Boston-based Clairity, marking a big milestone for women's health tech and potentially for women's health screening. I profiled Clairity's founder Dr. Connie Lehman three years ago, as part of a story on investment in Femtech. At the time, she told CNBC the accuracy of technology can help reduce over-screening for women who are presumed to be at risk, while helping to identify women who might otherwise not be monitored until they've already developed cancer. "By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere," she said in the company's announcement of the approval. But to save lives, the next big step is to ensure women have access to the breakthrough technology as a preventive screening. The American Medical Association will first need to issue a billing code, which for some AI-driven tools has been slow to come. That code will be crucial to securing insurance coverage. Feel free to send any tips, suggestions, story ideas and data to Bertha at Amazon Pharmacy on Tuesday announced new updates for caregivers and more than 50 million Medicare Part D beneficiaries. Launched in 2020, Amazon Pharmacy was formed out of the company's 2018 acquisition of the online pharmacy PillPack. The offering is now a full-service, digital pharmacy that can help support patients with both one-off and recurring prescriptions. Prime members in cities like Los Angeles and New York City are eligible for same-day medication deliveries. Amazon said that customers with Medicare insurance can now directly access PillPack's services, which means those with two or more prescriptions can have their medications sorted into individual tear-away packets labeled with the date and time. The company said these monthly shipments will reduce the need for patients to keep track of multiple pill bottles and help them stick to their routines, according to a release. Patients interested in accessing pre-sorted medications through PillPack can sign up by logging into Amazon Pharmacy. Amazon Pharmacy also introduced a new way for verified caregivers to help manage medications on behalf of their loved ones. Around one in every five adults in the U.S. are caring for an aging family member, according to AARP. Patients can invite trusted caregivers to help oversee their medications by submitting their phone number. The caregiver will receive a text with a link, have to confirm details about the patient in question, and then can begin managing the patient's medications through their own account. "These updates deliver what our customers have been asking for—simpler medication management for themselves and their loved ones," John Love, vice president of Amazon Pharmacy, said in a statement on Tuesday. Amazon's online pharmacy is a part of the company's multi-year effort to push into the health-care industry. The company acquired primary care provider One Medical for roughly $3.9 billion in July 2022. Read the full announcement here. Feel free to send any tips, suggestions, story ideas and data to Ashley at
